摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,4,5-trihydroxy-N-penta-1,3-dien-2-ylbenzamide

中文名称
——
中文别名
——
英文名称
3,4,5-trihydroxy-N-penta-1,3-dien-2-ylbenzamide
英文别名
——
3,4,5-trihydroxy-N-penta-1,3-dien-2-ylbenzamide化学式
CAS
——
化学式
C12H13NO4
mdl
——
分子量
235.24
InChiKey
NDMYHXSJWMYCKO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    89.8
  • 氢给体数:
    4
  • 氢受体数:
    4

文献信息

  • Nitric oxide donating derivatives for the treatment of cardiovascular disorders
    申请人:Tucker Joseph
    公开号:US20050080024A1
    公开(公告)日:2005-04-14
    Compounds comprising nitric oxide derivatives of stilbenes, polyphenols and flavonoids and methods of their use are provided for treating patients suffering from any of hypercholesterolemia, vascular oxidative stress and endothelial dysfunction.
    本发明提供了由stilbenes、多和类黄酮亚硝酸盐生物组成的化合物,以及它们的使用方法,用于治疗患有高胆固醇血症、血管氧化应激和内皮功能障碍的患者。
  • Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
    申请人:Tucker Joseph
    公开号:US20050080021A1
    公开(公告)日:2005-04-14
    Compounds and methods are provided for treating patients suffering from any of hypercholesterolemia, vascular oxidative stress and endothelial dysfunction.
    提供了用于治疗患有高胆固醇血症、血管氧化应激和内皮功能障碍的患者的化合物和方法。
  • Treatment of diseases associated with the egr-1 enhancer element
    申请人:Wong Norman
    公开号:US20070099826A1
    公开(公告)日:2007-05-03
    Compounds and methods are provided for treating patients suffering from health condition associated with an expression state of a gene such as fertility disorders, cancer, proliferative diseases, vascular diseases, wounds requiring therapeutic intervention, inflammation, and pulmonary disorders by administering to said patient a compound capable of modulating egr-1 and/or an egr-1 response element consensus sequence thereby altering the expression state of said gene. Also described are new methods for screening compounds to identify effectors of egr-1 and/or egr-1 consensus sequence elements and methods for treating patients by administering such effectors to modulate egr-1 and/or egr-1 consensus sequences to thereby modify expression of genes associated therewith to in turn treat diseases or other physiological conditions associated with such gene expression.
查看更多